Hayden Ansinelli (@ansinelliradonc) 's Twitter Profile
Hayden Ansinelli

@ansinelliradonc

Father, Husband, Radiation Oncologist at @AZOncology, Tucson AZ. Views my own.

ID: 1576266506693799936

calendar_today01-10-2022 17:43:29

31 Tweet

73 Followers

207 Following

Andrew Farach, MD (@andrewfarach) 's Twitter Profile Photo

March is #ColorectalCancerAwarenessMonth! Thanks to Meteorologist Carrigan Chauvin for inviting me to discuss the importance of colorectal cancer screening this morning šŸŽ„ CW39 Houston Methodist MD #radonc cw39.com/cw39/tips-from…

Joost Verhoeff (@joostverhoeff) 's Twitter Profile Photo

šŸ“¢ Cancer patients with psychiatric disorders (schizophrenia, bipolar, or borderline personality disorder) receiving similar radiotherapy regimens have significantly lower Overall Survival rates compared to patients without psychiatric disorders. We should do better. šŸ§ šŸ”¬

šŸ“¢ Cancer patients with psychiatric disorders (schizophrenia, bipolar, or borderline personality disorder) receiving similar radiotherapy regimens 
have significantly lower Overall Survival rates compared to patients without psychiatric disorders. 

We should do better. šŸ§ šŸ”¬
Dr. Glaucomflecken (@dglaucomflecken) 's Twitter Profile Photo

Spent the week with my mom. Radiation and multiple surgeries for a high grade liposarcoma left her unable to sit for the better part of 8 months. Now here she is, sitting and cancer free.

Spent the week with my mom. Radiation and multiple surgeries for a high grade liposarcoma left her unable to sit for the better part of 8 months. Now here she is, sitting and cancer free.
Joe Y Chang (@joechangmd) 's Twitter Profile Photo

Randomized study published in Lancet today, showing 62% EFS improvement with Nivo + SABR compared with SABR alone in early stage NSCLC. I-SABR is a promising TX option. awbs://authors.elsevier.com/c/1hRV5V-4XL3dJ IASLC MD Anderson Cancer Center The Lancet Albert Koong, MD PhD Stephen V Liu, MD

Randomized study published in Lancet today, showing 62% EFS improvement with Nivo + SABR compared with SABR alone in early stage NSCLC. I-SABR is a promising TX option.

awbs://authors.elsevier.com/c/1hRV5V-4XL3dJ
<a href="/IASLC/">IASLC</a> 
<a href="/MDAndersonNews/">MD Anderson Cancer Center</a> <a href="/TheLancet/">The Lancet</a> <a href="/ACKoongMDPhD/">Albert Koong, MD PhD</a> 
<a href="/StephenVLiu/">Stephen V Liu, MD</a>
Raj Singh, MD (@raj_singh_md) 's Twitter Profile Photo

Sad to see that IMRT is not covered by UnitedHealthcare Ask UnitedHealthcare for limited stage small cell lung cancer, particularly given encouraging findings regarding dose escalation vs. SoC from two Phase II trials, known association of heart dose on survival, and National Comprehensive Cancer Network (NCCN) recommending IMRT over 3D-CRT.

Emily Daugherty, MD (@nerdicasmaximus) 's Twitter Profile Photo

EviCore By Evernorth Anthem Blue Cross and Blue Shield denying IMRT over 3D for a young breast cancer in a patient < 40 - 3D plan not meeting constraints, plan sent. Denied. Staff told there is NO option for a ā€œpeerā€-to-peer or reconsideration. !? This should be a no brainer. Do better for my patient EviCore By Evernorth

the Radiosurgery Society (@the_rss) 's Twitter Profile Photo

Mark your calendar: The 2025 Radiosurgery Society Scientific Meeting will be held March 20-22, 2025 in Tucson, AZ. Look out for registration info in July! #2025RSS

Mark your calendar: The 2025 Radiosurgery Society Scientific Meeting will be held March 20-22, 2025 in Tucson, AZ. Look out for registration info in July! #2025RSS
Jeff Ryckman (@jryckman3) 's Twitter Profile Photo

Dear Humana, my patient with oligometastatic prostate cancer (CHAARTED-defined) qualifies for prostate-directed radiotherapy per STAMPEDE Arm H—a Phase III trial showing overall survival benefit. Despite 3D radiotherapy approval, IMRT was denied. I was denied peer-to-peer review

Andrew Farach, MD (@andrewfarach) 's Twitter Profile Photo

For anyone interested in the #300in10 mini-fellowship to develop expertise in #brachytherapy this is a must listen! šŸ‘‚ Thanks to Manuj Agarwal and Rebecca Krc for highlighting the work of the Houston Methodist MD #Bteam! Now 12 training sites in the šŸ‡ŗšŸ‡ø&šŸ‡ØšŸ‡¦ americanbrachytherapy.org/resources/fell…

Andrew Farach, MD (@andrewfarach) 's Twitter Profile Photo

Just ask Bob šŸŽØ, #brachytherapy is the ultimate in dose painting A great tx option for nodular #prostatecancer fossa recurrences in upfront & reRT settings. Allows for OAR sparing and dose escalation. #300in10 fellow collab sciencedirect.com/science/articl… #pcsm #radonc

American Brachy (@americanbrachy) 's Twitter Profile Photo

šŸš€ Ready to elevate your expertise? Register now for #ABSBrachy25 & join key thought leaders in Nashville! Don't miss the chance to connect, learn, and innovate in the field of #brachytherapy.šŸ™ļø #Brachytherapy bit.ly/4iCD1ae @andrewfarach marisa kollmeier DrKamrava

Jeff Ryckman (@jryckman3) 's Twitter Profile Photo

🚨 We’re hiring not one but TWO medical oncologists in Parkersburg, WV, a welcoming community with real need, a big heart, and a team that’s ready to support you. A chance to truly make a difference in a community of need: wvumedicine.wd1.myworkdayjobs.com/UHA/job/Camden…

🚨 We’re hiring not one but TWO medical oncologists in Parkersburg, WV, a welcoming community with real need, a big heart, and a team that’s ready to support you. A chance to truly make a difference in a community of need:
wvumedicine.wd1.myworkdayjobs.com/UHA/job/Camden…
Albert Attia (@albertattia7) 's Twitter Profile Photo

Hey BCBSM can you explain to me why you won’t approve prostate SBRT in a patient with intermediate risk prostate cancer? And then I come to find out you want a 3D comparison if I want to use IMRT? You clearly don’t care about the wellbeing of the patient. Despicable…